Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-directed first-line chemotherapy trial in metastatic pancreatic adenocarcinoma
ACTRN12610001047088Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Apr 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, oxaliplatin, folinic acid and fluorouracil in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Progression-free survival at 4 months. Started Apr 2012; status: completed.
02
Drugs
gemcitabineoxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12610001047088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001047088.